Literature DB >> 30429160

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).

Alice Cleynen1, Mehmet Samur2,3, Aurore Perrot4, Laure Buisson5,6, Sabrina Maheo5,6, Mariateresa Fulciniti2, Michel Attal5,6, Nikhil Munshi2,7, Hervé Avet-Loiseau5,6, Jill Corre5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30429160      PMCID： PMC6307986          DOI： 10.1182/blood-2018-09-876433

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  17 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.

Authors:  Gang An; Yan Xu; Lihui Shi; Dehui Zou; Shuhui Deng; Weiwei Sui; Zhenqing Xie; Mu Hao; Hong Chang; Lugui Qiu
Journal:  Leuk Res       Date:  2013-08-05       Impact factor: 3.156

3.  Natural history of t(11;14) multiple myeloma.

Authors:  A Lakshman; M Alhaj Moustafa; S V Rajkumar; A Dispenzieri; M A Gertz; F K Buadi; M Q Lacy; D Dingli; A L Fonder; S R Hayman; M A Hobbs; W I Gonsalves; Y L Hwa; P Kapoor; N Leung; R S Go; Y Lin; T V Kourelis; J A Lust; S J Russell; S R Zeldenrust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2017-06-27       Impact factor: 11.528

4.  Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.

Authors:  G P Kaufman; M A Gertz; A Dispenzieri; M Q Lacy; F K Buadi; D Dingli; S R Hayman; P Kapoor; J A Lust; S Russell; R S Go; Y L Hwa; R A Kyle; S V Rajkumar; S K Kumar
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

5.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

Review 6.  Genomics of Multiple Myeloma.

Authors:  Sebastien Robiou du Pont; Alice Cleynen; Charlotte Fontan; Michel Attal; Nikhil Munshi; Jill Corre; Hervé Avet-Loiseau
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

7.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 8.  Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-07       Impact factor: 10.047

9.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

10.  Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Authors:  N Weinhold; C J Heuck; A Rosenthal; S Thanendrarajan; C K Stein; F Van Rhee; M Zangari; A Hoering; E Tian; F E Davies; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2015-11-03       Impact factor: 11.528
View more
  7 in total

1.  Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.

Authors:  Anne Slomp; Laura M Moesbergen; Jia-Nan Gong; Marta Cuenca; Peter A von dem Borne; Pieter Sonneveld; David C S Huang; Monique C Minnema; Victor Peperzak
Journal:  Blood Adv       Date:  2019-12-23

Review 2.  Multiple myeloma with t(11;14): unique biology and evolving landscape.

Authors:  Susan Bal; Shaji K Kumar; Rafael Fonseca; Francesca Gay; Vania Tm Hungria; Ahmet Dogan; Luciano J Costa
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 3.  High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.

Authors:  Patrick Hagen; Jiwang Zhang; Kevin Barton
Journal:  Blood Cancer J       Date:  2022-05-30       Impact factor: 9.812

Review 4.  Risk factors in multiple myeloma: is it time for a revision?

Authors:  Jill Corre; Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2021-01-07       Impact factor: 25.476

5.  Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Authors:  Mehmet Kemal Samur; Mariateresa Fulciniti; Anil Aktas Samur; Abdul Hamid Bazarbachi; Yu-Tzu Tai; Rao Prabhala; Alejandro Alonso; Adam S Sperling; Timothy Campbell; Fabio Petrocca; Kristen Hege; Shari Kaiser; Hervé Avet Loiseau; Kenneth C Anderson; Nikhil C Munshi
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

6.  Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically.

Authors:  Mariaserena Giliberto; Deepak B Thimiri Govinda Raj; Andrea Cremaschi; Sigrid S Skånland; Alexandra Gade; Geir E Tjønnfjord; Fredrik Schjesvold; Ludvig A Munthe; Kjetil Taskén
Journal:  Mol Oncol       Date:  2022-03-12       Impact factor: 6.603

7.  What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?

Authors:  Wen Gao; Juan Du; Junru Liu; Huixing Zhou; Zhiyao Zhang; Yuan Jian; Guangzhong Yang; Guorong Wang; Ying Tian; Yanchen Li; Yin Wu; Weijun Fu; Juan Li; Wenming Chen
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.